Shlevin Harold H. sold $151K of GALT
Shlevin Harold H. sold 30,000 shares of GALECTIN THERAPEUTICS INC (GALT) at an average of $5.03 ($5.00–$5.04, $0.15M total) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size ($150,890.72) and post-transaction holdings (6,500 shares). The text does not include any new company fundamentals, guidance, trial results, or regulatory actions.
Market read
Traders may treat this as a low-signal sentiment datapoint; without new fundamentals, it is unlikely to drive a durable repricing.
What to watch
The article provides only the sale details; it does not state whether other insiders bought, whether the director’s total program size changed, or whether there were concurrent company-specific catalysts.
Background
This is an SEC Form 4 insider transaction disclosure for GALECTIN THERAPEUTICS (GALT) by director Shlevin Harold, executed via an open-market sale under a pre-arranged 10b5-1 plan.
Ticker impact
GALECTIN THERAPEUTICS director Shlevin Harold sold 30,000 shares in open-market trades at ~$5.00–$5.04 under a 10b5-1 plan.
Low near-term impact; any effect is likely sentiment-only and quickly mean-reverts.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying new operational/regulatory/financial catalyst in the text.
Market effects
No sector read-through; this is a single-company insider sale disclosure.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with perceived valuation risk; traders may watch for follow-on sales or reduced insider buying.
Key entities
- issuerGALECTIN THERAPEUTICS INC
Subject of the Form 4 insider sale disclosure; director Shlevin Harold sold 30,000 shares at ~$5.03 avg.
- insiderShlevin Harold H.
Director who executed the open-market sale under a 10b5-1 plan (trades 2026-06-26 to 2026-06-29).